SpectraCure is entering an important phase on its way to the market. The management team has been reorganized to maximize the utilization of each person’s skill set up. Jens Nilsen is appointed as the company’s new CEO from December 1st. Mr Nilsen says, “SpectraCure is entering a very exciting period with clinical studies both in North America and Europe which requires a strong focus”. Former CEO Masoud Khayyami will stay on as Chairman of the board and as such focus on steering a competent and active board going forward.